Jason Kwon, the Chief Strategy Officer of OpenAI, took to X to express his thoughts on the recent dismissal of a lawsuit filed by xAI against OpenAI. The lawsuit, which alleged that OpenAI orchestrated a scheme to poach eight xAI employees in 2025 to steal its trade secrets and source code, was dismissed by a U.S. district judge.Judge Dismisses Lawsuit, Citing Lack of EvidenceIn a post on Tuesday, Kwon suggested that the lawsuit was a reaction to Musk’s “0% chance of success” comment when he left OpenAI. Th ...

U.S. stock futures rose on Wednesday after closing higher on Tuesday. Futures of all the major benchmark indices were positive.He touted 53 all-time stock market highs while vowing to replace income tax with foreign tariffs and launching “Trump Accounts” to provide every American child with a tax-free investment stake in the equity markets.Meanwhile, Scott Bessent sidestepped $134 billion tariff refund questions, slamming corporate lawsuits as “ultimate welfare” following Trump's speech. The 10-year Treasur ...

Market Overview - U.S. stock futures rose on Wednesday after a positive close on Tuesday, with all major benchmark indices showing gains [1] - The Dow Jones increased by 0.14%, S&P 500 by 0.16%, Nasdaq 100 by 0.20%, and Russell 2000 by 0.42% [3] Company Performance - Workday Inc. (NASDAQ: WDAY) saw a premarket decline of 9.51% despite reporting upbeat fourth-quarter earnings, as forward guidance fell below estimates [4] - HP Inc. (NYSE: HPQ) dropped 5.16% after issuing second-quarter GAAP EPS guidance below expectations [4] - HSBC Holdings PLC (NYSE: HSBC) rose 4.43% following a 6% increase in net interest income to $34.8 billion for 2025, while also cutting 10% of its U.S.-based debt capital [4] - Nvidia Corp. (NASDAQ: NVDA) was up 0.44% with analysts expecting earnings of $1.53 per share on revenue of $65.87 billion [4] - Shell PLC (SHEL) maintains a strong price trend across all time frames, supported by a solid value score [5] Sector Insights - Consumer discretionary, information technology, and industrials sectors led the S&P 500 higher, while energy and health care stocks trended lower [6] Analyst Insights - Professor Jeremy Siegel maintains an optimistic outlook for the U.S. economy and equity markets in 2026, citing strong underlying private demand despite a softer 1.4% fourth-quarter GDP report [7] - Siegel anticipates a market rotation favoring small caps, industrials, and globally exposed companies, viewing potential energy-driven volatility as a recalibration rather than a cycle-ending shock [8]

British robotaxi startup Wayve announced on Wednesday it had raised $1.5 billion in fresh funding to bolster its global operations, pushing the Microsoft and Nvidia-backed company’s valuation to $8.6 billion. The funding round was led by Eclipse, Balderton, and SoftBank’s (OTC:SFTBY) Vision Fund 2, with fresh participation from Ontario Teachers' Pension Plan, Baillie Gifford, British Business Bank, Icehouse Ventures, Schroders Capital, and several other global institutional investors.Founded in 2017, Wayve ...

Core Viewpoint - Salesforce, Inc. is set to release its fourth-quarter earnings on February 25, with expectations of increased earnings per share and revenue compared to the previous year [1]. Financial Performance - Analysts anticipate Salesforce will report earnings of $3.04 per share, an increase from $2.78 per share in the same quarter last year [1]. - The consensus estimate for quarterly revenue is $11.18 billion, up from $9.99 billion reported in the previous year [1]. Analyst Expectations - The company has exceeded revenue estimates in seven of the last ten quarters, although it missed expectations in the most recent third quarter [2]. - Salesforce shares rose by 4.1% to close at $185.42 on Tuesday [2].

Core Insights - Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst estimates of $755.40 million [1] - The company achieved fourth-quarter adjusted earnings of $2.15 per share, exceeding estimates of $1.60 per share [1] - Following the earnings report, Axon Enterprise shares increased by 16.2% to $514.21 in pre-market trading [1] Financial Performance - Fourth-quarter revenue: $796.72 million, beating estimates by $41.32 million [1] - Adjusted earnings per share: $2.15, exceeding estimates by $0.55 [1]

Novo Nordisk A/S (NYSE:NVO) announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027.The price reduction will affect the obesity injection Wegovy, its pill counterpart, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus. The new list price for these medications will be $675 per month, a significant drop from their current prices, which range from $1,027 to $1,350 per month.According to Millar, out-of-pocket costs for commercially insured pati ...

Treasury Secretary Scott Bessent refused to commit to issuing $134 billion in potential tariff refunds during a post-State of the Union interview, instead framing corporate demands for repayment as a form of government handout.The Refund Standoff“We will follow the ruling of the lower court,” Bessent stated, emphasizing a 42-day waiting period before further action. However, he quickly pivoted to a populist defense of the administration's refusal to pay, suggesting that returning the funds would not benefit ...

Harvard Professor and former IMF First Deputy Managing Director Gita Gopinath has dismissed claims that the U.S. is facing a balance-of-payments (BoP) crisis, arguing that the administration's new 150-day tariffs are an ineffective tool for long-term economic stability.Diagnosis: Cholesterol, Not A Heart Attack“A 150-day tariff cannot reduce persistent trade deficits and the U.S. is not having a heart attack,” Gopinath posted on X, directly challenging the justification for invoking Section 122 of the Trade ...

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.Earnings Beat Drives After-Hours RallyShares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.Its revenue also increased by $39.80 million from a year earlier.The fourth-qua ...